Cullinan Therapeutics (CGEM) vs Monte Rosa Therapeutics (GLUE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Cullinan Therapeutics (CGEM) has outperformed Monte Rosa Therapeutics (GLUE) over the past year, gaining 165.4% versus a gain of 37.8%. Over five years, CGEM leads with a -37.5% price change compared with -52.0% for GLUE. Cullinan Therapeutics is the larger company by market cap ($960.6 million vs $867.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGEM | GLUE |
|---|---|---|
| Share price | $15.63 | $10.17 |
| Market cap | $960.59M | $867.64M |
| 1-day change | -3.82% | +3.04% |
| YTD return | +51.01% | -35.14% |
| 1-year return | +165.37% | +37.80% |
| 5-year return | -37.48% | -52.03% |
| EPS (TTM) | $-3.11 | $-1.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $23.19 | $25.77 |
| 52-week low | $5.85 | $7.44 |
| Distance from 52-week high | -32.60% | -60.54% |
| Average volume | 868.12K | 1.31M |
| Shares outstanding | 61.46M | 85.31M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CGEM has outperformed GLUE by 127.6 percentage points over the past year.
CGEM vs GLUE FAQ
Which is bigger, Cullinan Therapeutics or Monte Rosa Therapeutics?
Cullinan Therapeutics (CGEM) is larger, with a market capitalization of $960.59M compared with $867.64M for Monte Rosa Therapeutics (GLUE).
Which stock has performed better over the past year, CGEM or GLUE?
CGEM returned +165.37% over the past 12 months, compared with +37.80% for GLUE (price return, excluding dividends). Past performance does not predict future results.
Are Cullinan Therapeutics and Monte Rosa Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.